序号 |
标题 |
次数 |
作者 |
发布时间 |
70291 |
Azide-PEG12-CH2CH2CH2-COOtBu |
62 |
zyl |
2024-12-18 |
70292 |
GNR-DOX-cRGD 阿霉素和cRGD共轭的金纳米棒 |
85 |
h |
2024-12-18 |
70293 |
Boc-Val-Cit-PAB-PNB(CAS:870487-10-8) |
94 |
WYQ |
2024-12-18 |
70294 |
MC (C5)-Val-Cit,CAS号:2504147-59-3 |
68 |
WYQ |
2024-12-18 |
70295 |
5-FAM-C3-SH |
133 |
zyl |
2024-12-18 |
70296 |
NOTA-gg Nle-CycMSHhex {(67)Ga-1,4,4DOTA-GGNle-CycMSHhex |
87 |
h |
2024-12-18 |
70297 |
cas:2353409-54-6 ,Mal-amido-PEG8-Val-Gly,马来酰亚胺-酰胺-八聚乙二醇-VAL-GLY |
113 |
kx |
2024-12-18 |
70298 |
MC-Val-Cit-PAB-OH(CAS:159857-80-4) |
111 |
WYQ |
2024-12-18 |
70299 |
叶酸靶向BQR-SS-DOX脂质体前药,BQR-SS-DOX/DSPE-PEG2000-FA,靶向脂质体定制服务 |
73 |
axc |
2024-12-18 |
70300 |
N3-C4-NHS ester,478801-48-8 |
76 |
zyl |
2024-12-18 |
70301 |
NOTA-GO 螯合剂NOTA偶联纳米石墨烯 |
98 |
h |
2024-12-18 |
70302 |
Fmoc-Ala-Ser(Psi(Me,Me)pro)-OH CAS:252554-78-2 |
69 |
WYQ |
2024-12-18 |
70303 |
CAS:863971-53-3,Fmoc-Val-Cit-PAB-PNP,抗体药物偶联物FMOC-VAL-CIT-PAB-PNP |
98 |
kx |
2024-12-18 |
70304 |
Cl-C6-PEG12-NHCO-C3-NHS,2727166-23-4烷基链 |
94 |
zyl |
2024-12-18 |
70305 |
PD-L1单抗修饰的尼洛替尼脂质体,LP-Nilotinib/αPDL1,αPDL1修饰的Nilotinib脂质体 |
110 |
axc |
2024-12-18 |
70306 |
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB CAS:2055042-69-6 |
74 |
WYQ |
2024-12-18 |
70307 |
Cl-C6-PEG9-NH2 hydrochloride-烷基链 |
67 |
zyl |
2024-12-18 |
70308 |
Fmoc-Val-Cit-PAB-OH CAS:159858-22-7 |
73 |
WYQ |
2024-12-18 |
70309 |
CAS:159857-80-4,MC-Val-Cit-PAB-OH ,MC-VAL-CIT-PAB中间体 |
67 |
kx |
2024-12-18 |
70310 |
Biotin-C6-amine,65953-56-2烷基链试剂 |
86 |
zyl |
2024-12-18 |
70311 |
鹿茸多肽脂质体水凝胶,Velvet,antler,peptides,liposome,hydrogel,VAP-Lip-Gel,脂质体纳米载体定制服务 |
88 |
axc |
2024-12-18 |
70312 |
NOTA-Bn-SCN-Aoc-BN(7-14)S-2-(4-异硫氰基苄基)-NOTA偶联BN(7-14) |
83 |
h |
2024-12-18 |
70313 |
CAS:2055048-57-0,Fmoc-PEG4-Ala-Ala-Asn-PAB ,芴甲氧羰基-四聚乙二醇-ALA-ALA ASN-PAB |
71 |
kx |
2024-12-18 |
70314 |
NH2-PEG3-C6-Cl,1261350-60-0 |
63 |
zyl |
2024-12-18 |
70315 |
MC-Val-Cit-PAB-PNP(CAS:159857-81-5) |
90 |
WYQ |
2024-12-18 |
70316 |
NOTA-HSA 大环配体NOTA偶联人血清白蛋白 |
65 |
h |
2024-12-18 |
70317 |
SPDP-Val-Cit-PAB-OH(N-琥珀酰亚胺基-3-(2-吡啶二硫)丙酸) |
54 |
WYQ |
2024-12-18 |
70318 |
鹿茸多肽脂质体,Velvet,antler,peptides,liposome,VAP-Lip,多功能载药脂质体定制服务 |
107 |
axc |
2024-12-18 |
70319 |
NOTA-西妥昔单抗-800CW NOTA-cetuximab-800CW |
62 |
h |
2024-12-18 |
70320 |
CAS:644981-35-1,Val-Cit-PAB-MMAE , ADC试剂 |
57 |
kx |
2024-12-18 |
70321 |
SPDP-Val-Cit-PAB-PNP,分子式:C33H39N7O9S2 |
76 |
WYQ |
2024-12-18 |
70322 |
Azido-PEG4-Ala-Ala-Asn(Trt)-PAB(CAS:2055042-67-4) |
127 |
WYQ |
2024-12-18 |
70323 |
负载黄芩苷脂质体的纳米纤维膜,BCL-LPs/PVA-CS,NFs,载药脂质体定制服务 |
119 |
axc |
2024-12-18 |
70324 |
Auristatin E(CAS:160800-57-7),澳瑞他汀E |
85 |
WYQ |
2024-12-18 |
70325 |
Amino-PEG10-C6 氨基-聚乙二醇10-C6 |
69 |
zyl |
2024-12-18 |
70326 |
2762519-08-2,endo-BCN-PEG4-Val-Cit-PAB-MMAE,(1R,8S,9S)-双环[6.1.0]壬-四聚乙二醇-VAL-CIT-PAB-MMAE |
69 |
kx |
2024-12-18 |
70327 |
MMAE(CAS:474645-27-7),一甲基澳瑞他汀E,Monomethyl auristatin E |
156 |
WYQ |
2024-12-18 |
70328 |
m-PEG1-C11-SH,117559-62-3,甲基-一聚乙二醇-C11-巯基 |
67 |
zyl |
2024-12-18 |
70329 |
CAS:1703768-74-4,Vipivotide tetraxetan Linker , ADC试剂 |
67 |
kx |
2024-12-18 |
70330 |
Thalidomide-O-Cn-NH2,沙利度胺-烷基链-氨基 |
64 |
zyl |
2024-12-18 |
70331 |
Mal-amido-PEG8-val-gly-PAB-OH CAS号:2353409-52-4 |
74 |
WYQ |
2024-12-18 |
70332 |
cas:1042435-35-7,2-(2-(2-(3-((2,5-Dioxopyrrolidin-1-yl)oxy)-3-oxopropoxy)ethoxy)ethoxy)ethyl acrylate,ADC定制 |
155 |
wyh |
2024-12-18 |
70333 |
Fmoc-PEG4-Ala-Ala-Asn-PAB,CAS号:2055048-57-0 |
77 |
WYQ |
2024-12-18 |
70334 |
CAS:1116086-09-9,Fmoc-Phe -Lys(Trt)-PAB-PNP , ADC试剂 |
69 |
kx |
2024-12-18 |
70335 |
DBCO-C12-amine 二苯并环辛炔-C12-胺 |
62 |
zyl |
2024-12-18 |